Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: astrocyte-derived neurotrophic factors - MANF Therapeutics

Drug Profile

Research programme: astrocyte-derived neurotrophic factors - MANF Therapeutics

Alternative Names: AMRS-001; CDNF - MANF Therapeutics; Conserved dopaminergic neurotrophic factor; MANF-based therapeutics - MANF Therapeutics; Mesencephalic astrocyte-derived neurotrophic factor; Recombinant MANF - MANF Therapeutics; rhMANF - MANF Therapeutics

Latest Information Update: 13 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amarantus Therapeutics; University of Miami
  • Developer Amarantus Bioscience Holdings; Generex Biotechnology Corporation; MANF Therapeutics
  • Class Antidementias; Antiparkinsonians; Cardiovascular therapies; Eye disorder therapies; Nerve growth factors; Recombinant proteins
  • Mechanism of Action Apoprotein inhibitors; Apoptosis inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa; Retinal artery occlusion
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Brain injuries; Diabetes mellitus; Glaucoma; Ischaemic heart disorders; Macular degeneration; Parkinson's disease; Retinal artery occlusion; Retinal vein occlusion; Retinitis pigmentosa; Spinocerebellar degeneration; Stroke
  • Research Alzheimer's disease
  • No development reported Amyotrophic lateral sclerosis

Most Recent Events

  • 11 Jun 2018 Preclinical development is ongoing for Ischaemic heart disorders in USA
  • 11 Jun 2018 Preclinical trials in Brain injuries in USA (Parenteral)
  • 11 Jun 2018 Pharmacodynamics data from preclinical trials in Brain injuries released by MANF Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top